Showing 1811-1820 of 2314 results for "".
- OpenAI Launches ChatGPT for Clinicians with New Healthcare-Focused Capabilitieshttps://modernod.com/news/openai-launches-chatgpt-for-clinicians-with-new-healthcare-focused-capabilities/2486805/Key Takeaways ChatGPT is being enhanced to better support clinicians by assisting with tasks like summarizing medical evidence, drafting documentation, and generating patient education materials
- AptarGroup Highlights New “Beat the Blink” Technologyhttps://modernod.com/news/aptargroup-highlights-new-beat-the-blink-technology/2485307/AptarGroup shared an overview of its portfolio of eye care solutions, including 'Beat the Blink,' a new eye care delivery system designed to improve dosing accuracy and enhance the patient experience by “beating the blink” reflex. The technology is currently part of
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Cloudbreak Pharma Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pingueculahttps://modernod.com/news/cloudbreak-pharma-announces-positive-phase-2-results-for-cbt-004-in-patients-with-vascularized-pinguecula/2482896/Cloudbreak Pharma announced positive topline results from its phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. The multicenter, randomized, double-maske
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons
- Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and Unlicensed Territorieshttps://modernod.com/news/nicox-and-kowa-sign-agreement-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories/2482889/Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excludin
- Sydnexis Announces European Commission Approval of Ryjunea, the First Treatment for Slowing the Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-european-commission-approval-of-ryjunea-first-treatment-for-slowing-the-progression-of-pediatric-myopia/2482839/The European Commission (EC) has granted marketing authorization for Sydnexis' SYD-101 (branded as Ryjunea), the company’s proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia.
- Bausch + Lomb Launches Lumify Preservative Free Redness Reliever Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-the-united-states/2482814/Bausch + Lomb announced the US launch of Lumify Preservative Free redness reliever eye drops, which the company describes as the first and only preservative-free over-the-counter (OTC) eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to m
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T